The complete guide to semaglutide

What is semaglutide?

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone the small intestine releases after meals. It belongs to a drug class called GLP-1 receptor agonists, which bind to and activate the body's natural GLP-1 receptors. Semaglutide was developed by Novo Nordisk and first approved by the FDA in 2017 for type 2 diabetes (Ozempic) and in 2021 for chronic weight management (Wegovy).

The molecule is structurally similar to native human GLP-1, with chemical modifications that make it resistant to enzymatic breakdown. Native GLP-1 has a half-life of roughly two minutes; semaglutide's half-life is about seven days. That extended duration is what allows once-weekly subcutaneous dosing rather than the multi-daily injections required by older GLP-1 medications.

Brand names that contain semaglutide

• Ozempic — once-weekly injection, FDA-approved for type 2 diabetes (max 2.0 mg).
• Wegovy — once-weekly injection, FDA-approved for chronic weight management (max 2.4 mg).
• Rybelsus — daily oral tablet, FDA-approved for type 2 diabetes.
• Compounded semaglutide — prepared by licensed U.S. compounding pharmacies. Same active ingredient; not FDA-reviewed.

How semaglutide works in the body

Semaglutide acts on GLP-1 receptors located across multiple organ systems. The weight-loss effect is the sum of several distinct mechanisms operating in parallel — which is why the medication produces results that diet alone usually cannot match.

1. Central appetite regulation

The strongest weight-loss effect comes from the brain, not the gut. Semaglutide crosses into the hypothalamus and brainstem, activating GLP-1 receptors in the arcuate nucleus and area postrema. These regions integrate hunger and satiety signals. Activation produces three observable changes:

• Earlier satiety — feeling full on smaller portions.
• Reduced reward response to highly palatable foods (sweets, fried foods, alcohol).
• A measurable drop in food noise — the intrusive, recurring thoughts about eating.

2. Slowed gastric emptying

Semaglutide slows the rate at which food leaves the stomach by 30–70% in the first weeks, normalizing somewhat over time. A meal that previously emptied in 90 minutes may take 3+ hours. The result is prolonged fullness — and the early-treatment side effects of nausea and reflux when meals are too large or too rich.

3. Glucose-dependent insulin release

Semaglutide stimulates the pancreas to release insulin, but only when blood sugar is elevated. This makes the medication effective for type 2 diabetes without the hypoglycemia risk of older insulin secretagogues. It also reduces post-meal glucose spikes, which lowers the energy crashes that drive late-afternoon snacking.

4. Reduced glucagon

It suppresses glucagon — the hormone that tells the liver to release stored glucose — which further stabilizes blood sugar between meals.

5. Indirect cardiovascular effects

The SUSTAIN-6 and SELECT trials demonstrated that semaglutide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with diabetes or established cardiovascular disease. The mechanism is partly weight loss, partly direct vascular effects, and partly improvements in blood pressure and lipids.

What is semaglutide approved for?

Semaglutide is sometimes prescribed off-label for related conditions where the underlying physiology overlaps — including polycystic ovary syndrome (PCOS), prediabetes, non-alcoholic fatty liver disease (NAFLD/MASLD), and weight regain after bariatric surgery. Off-label use is appropriate when supported by clinical judgment and informed consent.

Who is a candidate for semaglutide?

The FDA-approved criteria for chronic weight management are clear, and most reputable telehealth providers — including WeightlessRx — apply them as the floor for eligibility.

Standard eligibility (Wegovy criteria)

• Adults with a body mass index (BMI) of 30 or higher, OR
• Adults with a BMI of 27 or higher plus at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

See our full GLP-1 BMI eligibility breakdown for how this is calculated and which conditions qualify.

Who semaglutide is not appropriate for

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• History of pancreatitis (active or recurrent).
• Severe gastrointestinal disease, including gastroparesis.
• Active or recent eating disorder (anorexia nervosa, bulimia nervosa).
• Pregnancy, planned pregnancy, or breastfeeding. Patients of childbearing potential should use reliable contraception during treatment.
• Type 1 diabetes (semaglutide is not a substitute for insulin).
• Known hypersensitivity to semaglutide or any inactive ingredient.

Semaglutide dosing schedule

Semaglutide is dose-titrated upward over approximately 16–20 weeks. The slow ramp is intentional: it gives the GI tract time to adapt and dramatically reduces the rate of severe nausea. Skipping ahead does not produce faster weight loss; it produces faster side effects.

Standard Wegovy titration (FDA-approved)

Some patients reach their target weight at 1.0 mg or 1.7 mg and stay there. Others tolerate 2.4 mg easily and benefit from staying on it. The right dose is the lowest dose that produces durable progress with manageable side effects.

How and where to inject

• Once weekly, on the same day each week.
• Subcutaneous injection — abdomen (avoiding 2 inches around the navel), upper thigh, or back of the upper arm.
• Rotate sites to avoid lipohypertrophy (lumps under the skin).
• Time of day does not matter. Take with or without food.
• If you miss a dose: take it within 5 days of your scheduled day. If more than 5 days have passed, skip and resume next scheduled day. Do not double up.

What treatment looks like, week by week

Patient experience varies, but the following timeline is consistent enough that most clinicians use it to set expectations.

Expected results from semaglutide

The pivotal STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the most-cited evidence for what semaglutide produces.

Real-world results

Real-world weight loss tends to be slightly lower than trial averages, primarily because real patients miss doses, drop out, or never reach the maximum dose. Published real-world studies show 10–13% loss at one year. The patients who match or exceed trial results almost always share three habits: they stay on the maximum tolerated dose, they eat protein-forward meals, and they strength train.

Predictors of stronger response

• Higher starting BMI (more weight to lose).
• Reaching and tolerating the 2.4 mg dose.
• Adequate protein intake (1.2–1.6 g/kg body weight per day).
• Resistance training 2–3 times per week — see keeping muscle while losing weight.
• Consistent sleep (7+ hours).
• Treating underlying conditions (insulin resistance, hypothyroidism, sleep apnea).

What "non-response" looks like

Roughly 10–15% of patients lose less than 5% of body weight by 16 weeks at full dose. This is the FDA-defined threshold for non-response. Common reasons: undiagnosed insulin resistance, untreated thyroid disease, medication interactions, or simple under-titration. See why your GLP-1 might not be working.

Side effects of semaglutide

Most side effects are gastrointestinal, dose-dependent, and time-limited. They peak in the first 1–2 weeks of each new dose and usually resolve as the body adapts.

Common side effects (>10% of patients)

• Nausea — affects ~44% of patients in trials. Typically mild and improves within 1–2 weeks of each dose increase. Full management strategies →
• Diarrhea — ~30%, often early in treatment.
• Constipation — ~24%, often later. Caused by slowed gastric emptying and reduced food/fiber intake.
• Vomiting — ~24%, almost always tied to overeating or eating high-fat meals.
• Headache — ~14%, often related to dehydration.
• Fatigue — ~11%, especially during dose increases.

Less common but notable

• Reflux / heartburn (~7%).
• Dizziness (~7%).
• Abdominal pain (~10%).
• Injection site reactions — small bruise, mild redness.
• Hair shedding — typically rapid-loss-related, not the medication itself. Resolves with adequate protein and stable weight.
• "Ozempic face" — loss of facial fat that exposes underlying bone structure. This is rapid weight loss, not a unique medication effect.

How to minimize side effects

• Eat smaller meals — half your previous portion is a good starting point.
• Prioritize protein. Avoid high-fat or fried foods, especially in the first weeks of each new dose.
• Hydrate aggressively — 80+ oz water daily.
• Add fiber gradually — psyllium husk or chia seeds help with constipation.
• Limit alcohol. See GLP-1s and alcohol for what changes.
• If a dose increase produces severe symptoms, talk to your clinician about staying at the previous dose for an additional 2–4 weeks before advancing.

Serious risks and contraindications

Serious adverse events are uncommon but real. Patients should understand what to watch for.

Boxed warning: thyroid C-cell tumors

Semaglutide carries an FDA boxed warning based on rodent studies showing thyroid C-cell tumors at high doses. The signal has not been confirmed in humans, but the warning means semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Symptoms requiring urgent evaluation: a lump in the neck, hoarseness that does not resolve, trouble swallowing, or shortness of breath.

Pancreatitis

Acute pancreatitis has been reported. Risk is low but elevated in patients with prior pancreatitis or significant gallstone disease. Severe persistent abdominal pain that radiates to the back and is associated with vomiting requires immediate medical attention. Semaglutide should be discontinued if pancreatitis is suspected.

Gallbladder disease

Rapid weight loss of any kind increases gallstone formation. Patients losing more than 1.5 kg per week have a measurably higher risk. Symptoms: right upper quadrant pain after fatty meals, fever, jaundice. Treatment is typically gallbladder removal (cholecystectomy).

Acute kidney injury

Most cases of kidney injury on semaglutide are downstream of dehydration from severe nausea, vomiting, or diarrhea. Stay hydrated; report persistent vomiting.

Hypoglycemia

Risk is low in non-diabetic patients (semaglutide's insulin effect is glucose-dependent). Risk rises significantly when semaglutide is combined with sulfonylureas or insulin in diabetic patients — those medications often need to be reduced.

Diabetic retinopathy

In patients with established type 2 diabetes, rapid improvement in glycemic control can transiently worsen pre-existing retinopathy. A baseline eye exam is reasonable in diabetic patients before starting.

Mental health

Post-marketing reports have raised concern about mood changes and suicidal ideation. Large analyses have not found a clear causal link, but patients with active mental health conditions should be monitored. Report new-onset depression or thoughts of self-harm immediately.

Drug interactions to know

• Insulin and sulfonylureas — combined use raises hypoglycemia risk. Doses often need to be reduced.
• Oral contraceptives — slowed gastric emptying may reduce absorption, especially during dose escalation. Consider a backup method for the first 4 weeks of each new dose.
• Warfarin and other narrow-therapeutic-index drugs — slowed absorption may shift levels. INR monitoring is reasonable.
• Levothyroxine — absorption may be modestly affected. Take levothyroxine on an empty stomach as usual; recheck TSH 6–8 weeks after starting.
• Alcohol — not a pharmacokinetic interaction, but most patients report dramatically reduced tolerance. Read more →

What happens if you stop semaglutide

This is the most important question patients fail to ask before starting — and the most predictable disappointment in obesity medicine.

Why weight comes back

Weight regain after stopping is biological, not behavioral. The body defends a weight set point through three mechanisms that re-engage when the medication is removed:

• Ghrelin and other hunger hormones rebound, often above baseline.
• Resting metabolic rate stays slightly suppressed for months to years after weight loss (metabolic adaptation).
• Food noise, dampened by GLP-1 activity, returns within weeks.

See why weight keeps coming back for a deeper explanation.

Maintenance strategies

• Continued full-dose treatment. Many patients stay on 1.0–2.4 mg indefinitely. This produces the most durable results.
• Reduced maintenance dose. Some patients stabilize at 0.5 mg or 1.0 mg with adequate protein and exercise.
• Microdosing. Some clinicians use sub-therapeutic doses for maintenance — see our GLP-1 microdosing overview.
• Structured taper plus intensive lifestyle support. Possible but requires real behavioral capacity.

Protecting muscle and long-term health

Semaglutide's biggest blind spot is body composition. Weight loss from any source — diet, surgery, medication — is roughly 25–40% lean mass without resistance training. That muscle loss matters because muscle is the largest reservoir of insulin sensitivity, the dominant driver of resting metabolic rate, and the foundation of long-term physical function.

Two non-negotiable habits

• Protein. 1.2–1.6 g per kg of body weight per day. For most adults, that means 30–40 g per meal. Whey, lean meat, eggs, Greek yogurt, tofu, and protein powders all qualify.
• Resistance training. 2–3 sessions per week, focused on compound movements (squat, hinge, push, pull). Twenty minutes per session, three days per week, is enough to preserve almost all lean mass during weight loss.

Read the full protocol in keeping muscle while losing weight.

Brand-name vs compounded semaglutide

This distinction matters more than most patients realize.

Compounded semaglutide became widely available during the FDA-declared shortage of brand semaglutide (2022–2024). Production by 503A and 503B pharmacies is legal under federal compounding law, but standards vary significantly between pharmacies. Patients considering compounded semaglutide should verify their telehealth provider works with state-licensed pharmacies and that prescriptions are reviewed by a licensed clinician — not auto-issued.

Semaglutide vs tirzepatide

Tirzepatide (Mounjaro, Zepbound) is the next-generation option. The difference is mechanistic: semaglutide acts only on GLP-1 receptors; tirzepatide acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual action produces stronger weight loss in head-to-head and indirect comparisons.

Both medications are appropriate first-line options. Semaglutide has more long-term cardiovascular evidence; tirzepatide produces more weight loss on average. Patients who plateau on semaglutide often respond well to switching. Read the full comparison →

Common misconceptions about semaglutide

Frequently asked questions

Educational summary

Semaglutide is a GLP-1 receptor agonist that quiets appetite, slows gastric emptying, and improves glucose handling. At full dose, it produces an average of 14.9% weight loss in clinical trials and somewhat less in real-world use. It is taken as a once-weekly subcutaneous injection, dose-titrated over 16+ weeks, and is most effective when continued long-term alongside adequate protein and resistance training. The most common side effects are gastrointestinal and time-limited; serious adverse events (pancreatitis, gallbladder disease) are uncommon. Stopping the medication usually returns appetite and weight toward baseline, which is why most clinicians treat obesity as a chronic condition requiring chronic treatment.

This page is one of several in our complete-guide series. Continue with: